Susquehanna Fundamental Investments’s Akero Therapeutics AKRO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,080	Closed	-$669K	–	559
2025 Q3	$669K	Hold	14,080	–	–	0.03%	392
2025 Q2	$751K	Sell	14,080 -10,641	-43%	-$484K	0.02%	497
2025 Q1	$1M	Buy	24,721 +16,331	+195%	+$692K	0.01%	689
2024 Q4	$233K	Buy	+8,390	New	+$254K	﹤0.01%	981

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna Fundamental Investments's AKRO Position: Q4 2025 in Review

Susquehanna Fundamental Investments sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 14,080 shares — an estimated $669K sold.

Susquehanna Fundamental Investments first reported a position in AKRO in Q4 2024 and held it in 4 quarters. The position peaked at $1M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Susquehanna Fundamental Investments reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 14,080 Akero Therapeutics shares in Q4 2025, an estimated $669K.
Susquehanna Fundamental Investments first reported a position in Akero Therapeutics in Q4 2024 and held it in 4 quarters.
Susquehanna Fundamental Investments's Akero Therapeutics position peaked at $1M in Q1 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2025, filed 17 Feb 2026.